HopeStage
Back to all studies
CompletedNCT01023659

Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts

Medication studyAges 18+CanadaAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2010
Recruitment status
Completed
Enrollment listed in the registry
893
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
Over 18 Years
Official registry ID
NCT01023659
Official title
Show the full official title

An Innovative Approach to Maximizing the Impact of Efficacious Pharmacotherapies on Smoking Cessation Attempts.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including bupropion and varenicline.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies